Ashish Atreja|Sameer Khan|J Rogers|Emamuzo Otobo|Nilay A. Patel|Thomas Ullman|J F Colombel|Shirley M. Moore|Bruce E. Sands
Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial
Icahn School of Medicine at Mount Sinai|Icahn School of Medicine at Mount Sinai|Icahn School of Medicine at Mount Sinai|Icahn School of Medicine at Mount Sinai|Icahn School of Medicine at Mount Sinai|Icahn School of Medicine at Mount Sinai|Icahn School of Medicine at Mount Sinai|Case Western Reserve University|Icahn School of Medicine at Mount Sinai
inflammatory bowel disease ibd chronic condition bowel affects 1 million people united states recurring nature disease makes ibd patients ideal candidates patientengaged care centered enhanced selfmanagement improved doctorpatient communication ibd optimal approaches management vary patients different phenotypes extent disease past surgical history hence single quality metric cannot define heterogeneous disease ibd unlike hypertension diabetes comprehensive assessment may provided complementing traditional quality metrics measures patients quality life qol application like healthpromisethe objective pragmatic randomized controlled trial determine impact healthpromise app improving outcomes quality care qoc qol patient adherence disease control resource utilization compared patient education app hypothesis patientcentric selfmonitoring collaborative decision support platform lead sustainable improvement overall qol ibd patientsparticipants recruited facetoface visits randomized either interventional ie healthpromise control ie education app patients healthpromise arm able update information receive disease summary quality metrics graph showing trend qol sibdq scores resource utilization time providers use data collaborative decision making quality improvement interventions point care patients control arm enter data baseline office visits end study receive decision support trend qol alert dashboard viewsenrollment trial starting first quarter 2015 intended 300 patients ibd recruited study 11 allocation ratio primary endpoint number quality indicators met healthpromise versus control arm secondary endpoints include decrease number emergency visits due ibd decrease number hospitalization due ibd change generic qol score baseline proportion patients group meet eligible outpatient quality metrics proportion patients disease control group addition plan conduct protocol analysis intervention patients adequate healthpromise utilization 6 logins data entry week 0 week 52 achieving mentioned primary secondary endpointshealthpromise unique cloudbased patientreported outcome pro decision support tool empowers patients providers patients track qol symptoms providers use visual data real time integrated electronic health records ehrs provide better care entire patient population using pragmatic trial design hope show ibd patients participate care share decision making appreciably improved outcomes compared patients notclinicaltrialsgov nct02322307 httpsclinicaltrialsgovct2shownct02322307 archived webcite httpwwwwebcitationorg6w8poythr